Rs 294.84 cr deposited by drug firms for overcharging in FY17

Image
Press Trust of India New Delhi
Last Updated : Mar 10 2017 | 5:07 PM IST
Pharmaceutical firms have deposited Rs 294.84 crore in the current fiscal so far against demand notices issued by the government for overcharging patients for scheduled drugs, Parliament was informed today.
As on February 28, 2017, Rs 294.84 crore has been deposited for 2016-17 by pharmaceutical companies against demand notices issued by government for overcharging patients for scheduled medicines, Minister of State for Chemicals and Fertilisers Mansukh L Mandaviya told Rajya Sabha in a written reply.
There were 120 cases of overcharging in the period, he added.
The provisions of the Drugs (Prices Control) Order "empower the government to direct the manufacturer to deposit the overcharged amount along with the interest thereon from the date of overcharging, in addition to the penalty," Mandaviya said.
In a separate reply, he said that of the 23 medical devices regulated as 'drugs', only three devices namely condom, intra uterine device containing copper and coronary stents have been included in the Schedule-I of DPCO, 2013, and are under price control.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 10 2017 | 5:07 PM IST

Next Story